Why the study?
Are VKA-based and DOAC-based antithrombotic strategies associated with lower risk of MACE and NACE compared with platelet inhibition alone in patients with atrial fibrillation and acute coronary syndrome undergoing PCI?
Cohort (n=15,358)
Yes
Are VKA-based and DOAC-based antithrombotic strategies associated with lower risk of MACE and NACE compared with platelet inhibition alone in patients with atrial fibrillation and acute coronary syndrome undergoing PCI?
Answers are grounded in this paper and cite their sources.
In nationwide Swedish registry data of AF patients undergoing PCI for ACS, oral anticoagulation use rose substantially from 2010 to 2021, and both DOAC- and VKA-based strategies were associated with reduced MACE and NACE compared with antiplatelet therapy alone.
AIMS: The aim of this study was to study temporal changes in antithrombotic therapy and to assess associations between common treatment strategies and clinical outcomes. METHODS: Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing PCI between 2010 and 2022 were identified from the SWEDEHEART registry. The three most common antithrombotic treatment strategies were: 1. Vitamin K antagonist (VKA)-based, 2. Direct oral anticoagulant (DOAC)-based, and 3. Platelet inhibition (PI) only. Outcomes were major adverse cardiovascular events (MACE; all-cause death, myocardial infarction (MI), or stroke), and net adverse cardiovascular event (NACE; MACE or major bleeding). Cox regression models were created to adjust for differences in baseline characteristics. RESULTS: In total, 15,358 patients were included, 29% were women and median age was 76 years. At discharge, 4155 (27%) received VKA-based, 4962 (32%) DOAC-based therapy, and 6241 (41%) PI only. The proportion treated with oral anticoagulants increased from 27% in 2010 to 82% in 2021. VKA-, and DOAC-based strategies were both associated with adjusted lower adjusted risk of MACE, (aHR 0.80, 95% CI 0.73-0.89) and (aHR 0.82, 95% CI 0.74-0.90) and NACE (aHR 0.86, 95% CI 0.78-0.94) and (aHR 0.85, 95% CI 0.77-0.93), respectively, compared with PI only, with no difference between the two OAC strategies. CONCLUSIONS: In patients with AF undergoing PCI for ACS, the use of oral anticoagulants increased over time. Both a VKA- and DOAC-based strategy were associated with lower MACE and NACE, with no significant difference between the two strategies.
No takes yet. Share an insight, caveat, or question.
Skibniewski et al. (2026) conducted a cohort in Atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention (n=15,358). Direct oral anticoagulant (DOAC)-based or Vitamin K antagonist (VKA)-based antithrombotic therapy vs. Platelet inhibition (PI) only was evaluated on Major adverse cardiovascular events (MACE; all-cause death, myocardial infarction, or stroke) (aHR 0.82, 95% CI 0.74-0.90).
Synapse has enriched 10 related papers. Consider them for comparative context: